Ayurveda Intervention in moderate and severe Covid-19

A study of Gorochanadi Vati as an add on efficacy in moderate and severe Covid - 19 Positive subjects with reduced oxygen saturation - Covid-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034114

Enrollment

Registered

2021-06-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J09- Influenza due to certain identified influenza viruses

Interventions

Intervention1: Standard Care for moderate and severe Covid-19 subjects plus Tab Gorochanadi Vati 125 mg, 3 tab 3 times a day after food for 3 days: Standard Care for moderate and severe Covid-19 subje

Eligibility

Inclusion criteria

Inclusion criteria: 1. Typical or atypical clinical presentation of acute onset febrile illness with sore throat and dry cough with or without shortness of breath and a RT_PCR based laboratory confirmation test for COVID-19 2. Patients with either gender, 21 to 70 years age 3. Patients with moderate and severe Covid â?? 19 disease with SPO2 less than 94% 4. Patients willing to participate and sign an informed consent Understands and agrees to comply with planned study procedures.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from COVID-19 Disease with SpO2 level below 80% as judged by a physician 2. Severe, Unstable, Uncontrolled co-existent medical illness such as Diabetes, Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other disease of concern which may put the patient at increased risk during the study 3. Active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy. 4. Patients on complete parenteral nutrition 5. Patients who are likely to worsen or ventilator support due to any reason 6. Pregnancy and lactation 7. Physician decision that involvement in the study is not in the patientÂ´s best interest

Design outcomes

Primary

Measure	Time frame
Clinical symptoms and SpO2 saturation and oxygen requirementTimepoint: Baseline, Day 1, Day 2, Bay 3	—

Secondary

Measure	Time frame
Not applicableTimepoint: Not applicable	—

Countries

India

Contacts

Public ContactDr Suhas Kumar Shetty

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital

profpnrao@gmail.com09448064277

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026